Dyadic International (NASDAQ:DYAI – Get Rating) is scheduled to announce its earnings results after the market closes on Thursday, May 12th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Dyadic International (NASDAQ:DYAI – Get Rating) last issued its quarterly earnings results on Tuesday, March 29th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.11). The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $5.63 million. Dyadic International had a negative return on equity of 58.65% and a negative net margin of 543.68%. On average, analysts expect Dyadic International to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of DYAI opened at $2.23 on Thursday. Dyadic International has a twelve month low of $2.10 and a twelve month high of $6.89. The company has a 50 day moving average of $2.99 and a 200-day moving average of $3.66.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in DYAI. Millennium Management LLC lifted its holdings in Dyadic International by 12.3% during the 3rd quarter. Millennium Management LLC now owns 301,489 shares of the biotechnology company’s stock valued at $1,676,000 after purchasing an additional 33,042 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Dyadic International during the 3rd quarter worth $68,000. Morgan Stanley increased its position in Dyadic International by 1,167.3% during the 2nd quarter. Morgan Stanley now owns 13,991 shares of the biotechnology company’s stock worth $51,000 after buying an additional 12,887 shares during the period. Finally, Royal Bank of Canada increased its position in Dyadic International by 77.9% during the 2nd quarter. Royal Bank of Canada now owns 6,969 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,051 shares during the period. 26.12% of the stock is owned by institutional investors.
About Dyadic International (Get Rating)
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
- Get a free copy of the StockNews.com research report on Dyadic International (DYAI)
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
- What’s Next For Starbucks (NASDAQ: SBUX)?
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.